


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

“TDI01” SUSPENSION OBTAINED APPROVAL FOR PNEUMOCONIOSIS CLINICAL TRIAL

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that clinical trial for the treatment of pneumoconiosis with the Category I innovative medicine “TDI01” suspension self-developed by the Group has been approved by the National Medical Products Administrations of China. TDI01 is an inhibitor acting on new target of Rho/Rho associated coiled-coil containing protein kinase 2 (ROCK2) with high selectivity, and a “significant new drug” of the 13th Five-Year Plan of China. The Phase I clinical trial of the innovative medicine has been completed in the United States with a good safety profile, and a bridge study is currently being carried out in China. TDI01 was previously approved for clinical trial in China for the treatment of idiopathic pulmonary fibrosis, and pneumoconiosis is its second indication approved for clinical trial. The Group will continue to explore its application in fibrosis and related areas.

Pneumoconiosis is a systemic disease caused by diffuse fibrosis (scarring) of the lung tissue due to the inhalation of industrial dust (dust) over a long period of time during occupational activities and the retention of dust in the lungs. It causes symptoms such as coughing, chest tightness, shortness of breath and difficulty in breathing, and has a serious impact on pulmonary function of patients. At present, there is no effective medicine and measures for treatment in both China and overseas. TDI01 has shown significant improvement in pathological score and pulmonary function in pneumoconiosis models and the Group will actively advance the progress of the human clinical trial of TDI01.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 8 March 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.